DIVISLAB vs ORCHPHARMA: Stock Comparison

Divis Laboratories Ltd vs Orchid Pharma Limited

Live data: 22 July 2026, 3:00 PM IST • Source: NSE and company filings

Divis Laboratories Ltd is the larger company by market capitalisation. Divis Laboratories Ltd shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Divis Laboratories Ltd and Orchid Pharma Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, DIVISLAB is more favourable on 12 of 13 scored metrics and ORCHPHARMA on 1These counts are context-free and are not an overall rating.

Key Differences

Market Cap
DIVISLAB is the larger company
₹1.96 L Cr vs ₹5,072 Cr
P/E Ratio
DIVISLAB has a lower P/E
75.8x vs 253.09x
P/B Ratio
ORCHPHARMA has a lower P/B
4.04x vs 11.61x
EPS
DIVISLAB has higher earnings per share
₹96.6 vs ₹4.01
Dividend Yield
DIVISLAB has a higher dividend yield
0.41% vs 0%
Revenue Growth (TTM YoY)
DIVISLAB has faster revenue growth
9.5% vs -1.5%
EPS Growth (TTM YoY)
DIVISLAB has faster EPS growth
13.6% vs 0%
Qtr Sales Growth
DIVISLAB has stronger quarterly sales growth
9.52% vs 0.05%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricDIVISLABORCHPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricDIVISLABORCHPHARMA
Live Price₹7,387.5₹1,000.1
Day Change0.78%-2.24%
Volume3.23 L81,675
52-Week High₹7,438.5₹1,119.8
52-Week Low₹5,636.5₹480
Distance from 52W High-0.69%-10.69%

Valuation

MetricDIVISLABORCHPHARMA
Market Cap₹1.96 L Cr₹5,072 Cr
P/E Ratio75.8x253.09x
P/B Ratio11.61x4.04x
EPS₹96.6₹4.01
Book Value₹631.37₹253.98
Dividend Yield0.41%0%

Growth

MetricDIVISLABORCHPHARMA
Revenue Growth (TTM YoY)9.5%-1.5%
EPS Growth (TTM YoY)13.6%0%
Qtr Sales Growth9.52%0.05%
Qtr Profit Growth13.4%4.26%

Profitability & Leverage

MetricDIVISLABORCHPHARMA
ROE16.5%2.12%
ROCE22%2.64%
Net Margin24.36%2.51%
Operating Margin32.6%5.07%
Debt to Equity0x0.28x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricDIVISLABORCHPHARMA
Promoter Holding51.88%69.84%
FII Holding20.2% 0.09 pp0.87% 0.3 pp
DII Holding19.38% 0.16 pp20.25% 0.86 pp
Public Holding8.54% 0.06 pp9.05% 0.55 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Divis Laboratories Ltd and Orchid Pharma Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.